Skip to main content

Press releases

13/10/26 - 13:00

Diasorin obtained FDA approval for Human Parvovirus B19 IgM and IgG on the Liaison XL (334.34 KB)
Products Immunodiagnostic

02/10/26 - 14:22

Margherita Sacerdoti appointed Investor Relations & ESG Senior Director at Diasorin (151.77 KB)
Other

19/06/26 - 15:45

Diasorin Announces FDA 510(K) Clearance and CLIA Waiver for the LIAISON NES Group A Streptococcus (GAS) Assay (174.02 KB)
Products Molecular

19/05/26 - 19:23

Diasorin Receives 510(K) Clearance for Fully Customizable LIAISON PLEX Gastrointestinal Flex Assay (179.61 KB)
Products Molecular

04/05/26 - 17:45

Diasorin Strengthens its Leadership of Immuno Division with the Appointment of Gabriele Allegri as President (158.42 KB)
Other

29/04/26 - 15:52

Shareholders' Meeting 2026 (166.06 KB)
Other

07/04/26 - 10:05

Communication on total amount of voting rights (7 April 2026) (225.44 KB)
Other

19/03/26 - 9:47

Diasorin signs strategic distribution agreement with McKesson Medical Surgical to expand access for the LIAISON NES molecular point‑of‑care platform (234.16 KB)
Other

24/02/26 - 7:06

Diasorin introduces next-generation LIAISON QuantiFERON-TB Gold Plus II assay for the U.S. in partnership with QIAGEN (154.8 KB)
Products Immunodiagnostic

03/02/26 - 12:13

Diasorin submits LIAISON NES Group A Strep molecular test to the U.S. FDA for 510(k) Clearance and CLIA Waiver (130.94 KB)
Products Molecular

29/01/26 - 7:03

Diasorin has been granted De novo authorization in the U.S. for the First Fully Automated Laboratory Test for Hepatitis Delta Virus (HDV) on the LIAISON XL (128.56 KB)
Products Immunodiagnostic

27/01/26 - 16:05

The Shareholders' meeting authorized the purchase of treasury shares, approved the amendment of art. 5 of the articles of association and authorized the cancellation of treasury shares. The Board approved the launch of the buyback plan. (120.91 KB)
Other

26/01/26 - 7:09

Diasorin signs exclusive distribution agreement for the LIAISON NES® molecular point‑of‑care platform and the Flu A/B, RSV & Covid‑19 panel (131.63 KB)
Products Molecular

23/01/26 - 17:49

Succession in the role of Group Chief Financial Officer of Diasorin. Alberto Donati appointed new Group Chief Financial Officer. (108.99 KB)
Other